252 related articles for article (PubMed ID: 24589307)
1. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.
Goéré D; Gras-Chaput N; Aupérin A; Flament C; Mariette C; Glehen O; Zitvogel L; Elias D
BMC Cancer; 2014 Mar; 14():148. PubMed ID: 24589307
[TBL] [Abstract][Full Text] [Related]
2. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Knödler M; Körfer J; Kunzmann V; Trojan J; Daum S; Schenk M; Kullmann F; Schroll S; Behringer D; Stahl M; Al-Batran SE; Hacker U; Ibach S; Lindhofer H; Lordick F
Br J Cancer; 2018 Aug; 119(3):296-302. PubMed ID: 29988111
[TBL] [Abstract][Full Text] [Related]
4. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
Desiderio J; Chao J; Melstrom L; Warner S; Tozzi F; Fong Y; Parisi A; Woo Y
Eur J Cancer; 2017 Jul; 79():1-14. PubMed ID: 28456089
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
[TBL] [Abstract][Full Text] [Related]
6. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.
Atanackovic D; Reinhard H; Meyer S; Spöck S; Grob T; Luetkens T; Yousef S; Cao Y; Hildebrandt Y; Templin J; Bartels K; Lajmi N; Stoiber H; Kröger N; Atz J; Seimetz D; Izbicki JR; Bokemeyer C
Hum Vaccin Immunother; 2013 Dec; 9(12):2533-42. PubMed ID: 23955093
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies.
Bretcha-Boix P; Farré-Alegre J; Sureda M; Dussan C; Pérez Ruixo JJ; Brugarolas Masllorens A
Clin Transl Oncol; 2010 Jun; 12(6):437-42. PubMed ID: 20534399
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.
Franko J; Ibrahim Z; Gusani NJ; Holtzman MP; Bartlett DL; Zeh HJ
Cancer; 2010 Aug; 116(16):3756-62. PubMed ID: 20564081
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of catumaxomab in gastric cancer.
Lordick F; Ott K; Weitz J; Jäger D
Expert Opin Biol Ther; 2008 Sep; 8(9):1407-15. PubMed ID: 18694358
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy.
Hultman B; Lind P; Glimelius B; Sundbom M; Nygren P; Haglund U; Mahteme H
Acta Oncol; 2013 May; 52(4):824-30. PubMed ID: 22974074
[TBL] [Abstract][Full Text] [Related]
11. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed].
Pocard M; Boige V
Bull Cancer; 2005 Feb; 92(2):151-4. PubMed ID: 15749644
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.
Shen P; Hawksworth J; Lovato J; Loggie BW; Geisinger KR; Fleming RA; Levine EA
Ann Surg Oncol; 2004 Feb; 11(2):178-86. PubMed ID: 14761921
[TBL] [Abstract][Full Text] [Related]
13. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
[TBL] [Abstract][Full Text] [Related]
14. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
[TBL] [Abstract][Full Text] [Related]
15. Catumaxomab: clinical development and future directions.
Linke R; Klein A; Seimetz D
MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
17. Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis.
Detroz B; Laurent S; Honoré P; Blaffart F; Limet R; Meurisse M
Acta Chir Belg; 2004 Aug; 104(4):377-83. PubMed ID: 15469146
[TBL] [Abstract][Full Text] [Related]
18. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.
Shen P; Levine EA; Hall J; Case D; Russell G; Fleming R; McQuellon R; Geisinger KR; Loggie BW
Arch Surg; 2003 Jan; 138(1):26-33. PubMed ID: 12511145
[TBL] [Abstract][Full Text] [Related]
19. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends.
Maggiori L; Elias D
Eur J Surg Oncol; 2010 Jul; 36(7):599-603. PubMed ID: 20605396
[TBL] [Abstract][Full Text] [Related]
20. [Resectional treatment of peritoneal carcinomatosis followed by intraperitoneal chemotherapy, practical aspects].
Elias D; Lasser P; Reynard B; Ducreux M; Pocard M
J Chir (Paris); 2003 Oct; 140(5):270-6. PubMed ID: 14631291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
